PT  - JOURNAL ARTICLE
AU  - Yang, Yuanchu J
AU  - Zeng, Chenjie
AU  - Schaffer, Kerry R
AU  - Tran, Tam C
AU  - Sauer, Peter J
AU  - Brown, Lincoln A
AU  - Park, Ben H
AU  - Denny, Joshua C
TI  - Association Between Major Adverse Cardiac Events and Hormone Therapy Usage in Prostate Cancer Patients of a Diverse Cohort
AID  - 10.1101/2024.10.09.24314666
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.09.24314666
4099  - http://medrxiv.org/content/early/2024/10/10/2024.10.09.24314666.short
4100  - http://medrxiv.org/content/early/2024/10/10/2024.10.09.24314666.full
AB  - Importance Hormone therapy (HT) has led to improved overall survival for prostate cancer patients, but may also increase cardiovascular risk.Objective To compare time-to-event for major adverse cardiovascular events (MACE) between those with and without HT use in prostate cancer patients.Design, Setting, and Participants This retrospective cohort study examined 5,156 participants from the All of Us Research Program who were diagnosed with prostate cancer and either treated or not treated with HT (defined as exposure to a GnRH agonist, GnRH antagonist, and/or anti-androgens). Time to MACE was defined using longitudinal electronic health record data. We evaluated whether HT use affected the risk of MACE using Cox regression adjusted for established cardiovascular risk factors.Exposures HT treatment (HT-treated study group), non-HT treatment (control group without HT but with surgery, radiation treatment, and/or non-HT medical therapy), or no treatment (active surveillance control group).Main Outcomes and Measures Time-to-event for MACE, which is defined as the interval between the start of treatment (or first prostate cancer diagnosis for the no treatment group) and the date of MACE. Participants who did not develop a MACE were right censored at their last healthcare provider visit.Results The final cohort included 5,156 participants; 851 in the HT treatment group, 624 in the non-HT treatment group, and 3,681 in the no treatment group. In participants with pre-treatment dyslipidemia, HT was found to be associated increased risk of MACE (HR, 1.52; 95% CI, 1.19-1.95; P <.001), while in those without pre-existing dyslipidemia, no association were found (HR, 0.96; 95% CI, 0.71-1.30; P = .81). Similar patterns were found across race and ethnicity groups. The combined androgen blockade was statistically significantly associated with MACE in participants with pre-existing dyslipidemia (HR, 1.58; 95% CI, 1.13-2.19; P= .006) and no association in participants without pre-existing dyslipidemia (HR, 0.96; 95% CI, 0.71-1.30; P= .81). We also observed that HT was associated with prolongation of the QTc interval (P= .02).Conclusions and Relevance HT treatment was associated with an increased risk for MACE participants with pre-existing dyslipidemia. These results suggest that increased risk stratification can help improve CV outcomes when deciding treatment regimens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers (1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA: AOD21037, AOD22003, AOD16037, AOD21041), Federally Qualified Health Centers (HHSN 263201600085U), Data and Research Center (5 U2C OD023196), Biobank (1 U24 OD023121), The Participant Center (U24 OD023176), Participant Technology Systems Center (1 U24 OD023163), Communications and Engagement (3 OT2 OD023205; 3 OT2 OD023206), and Community Partners (1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276). This work was supported by the National Human Genome Research Program Intramural Research Program, grant number: ZIA HG200417. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The All of Us research program institutional review board has determined this usage to be non-human subject research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData from participants in the All of Us cohort is available through approved access from the All of Us researcher workbench. https://workbench.researchallofus.org/